LEADER 03889nam 2200853z- 450 001 9910576888003321 005 20231214133428.0 035 $a(CKB)5720000000008294 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/84432 035 $a(EXLCZ)995720000000008294 100 $a20202206d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAlbumin-Based Drug Delivery Systems 210 1$aBasel :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2022. 215 $a1 electronic resource (162 pages) 311 $a3-0365-4108-X 311 $a3-0365-4107-1 330 $aAlbumin is playing an increasing role as a versatile, biodegradable drug carrier in clinical theranostics. By applying different techniques, smart drug-delivery systems can be developed from albumin in order to improve drug delivery of different active pharmaceutical ingredients, even small-molecule drugs, peptides or enzymes. Principally, three drug delivery technologies can be distinguished for binding small-molecule or peptide drugs through the charged amino acids, carboxyl, and amino groups of albumin: physical or covalent binding of the drug to albumin through a ligand- or protein-binding group, the fusion of drug with albumin or the encapsulation of drugs into albumin nanoparticles. The accumulation of albumin in inflamed tissues and solid tumours forms the rationale for developing albumin-based drug delivery systems for targeted drug delivery. Besides tumour therapy, albumin-based drug delivery systems can be successfully applied as anti-inflammatory and anti-thrombotic coating for medical devices. The development and optimization of albumin nanoparticles may also be a rational and promising tool for conventional or alternative administration routes in order to improve therapy. This collection provides an overview of the significant scientific research works in this field, which may inspire researchers towards further development and utilization of these smart drug delivery systems. 606 $aMedicine 610 $aplasma half-life extension 610 $aalbumin conjugation 610 $ain vivo glucose-lowering activity 610 $aglucagon-like peptide-1 610 $aquality by design 610 $arapid equilibrium dialysis 610 $amuco-adhesion 610 $abrain PAMPA 610 $aRPMI 2650 nasal epithelial cell 610 $ahuman serum albumin 610 $adimerization 610 $adoxorubicin 610 $aenhanced permeability and retention effect 610 $aantitumor 610 $aArthrobacter globiformis 610 $agout 610 $ahalf-life extension 610 $ainverse electron demand Diels-Alder reaction 610 $asite-specific albumin conjugation 610 $athermostability 610 $aurate oxidase 610 $aalbumin 610 $aanti-thrombotic 610 $aCD39 610 $acoating of medical devices 610 $astent coating 610 $atherapeutic fusion protein 610 $aconjugates 610 $avanadium 610 $acancer 610 $aprodrug 610 $ahydrogels 610 $aEPR/ESR spectroscopy 610 $arelease behavior 610 $adisulfide 610 $aglioma 610 $aconjugate 610 $aalbumin binding moieties 610 $apeptides 610 $aEvans blue 610 $a4-(p-iodophenyl)butyric acid 610 $aintegrin ?v?6 610 $aintegrin ?v?6 binding peptide 610 $aimproved pharmacokinetics 610 $aPET imaging 615 0$aMedicine. 702 $aKatona$b Gábor 906 $aBOOK 912 $a9910576888003321 996 $aAlbumin-Based Drug Delivery Systems$93040922 997 $aUNINA